Maykin Ho

CIK: 0001646395

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (8.3%)

Derivative conversions

Awards (A)16 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)6 (25.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (4)

AGIO

AGIOS PHARMACEUTICALS, INC.

Director

KYNB

KYNTRA BIO, INC.

Director

BMRN

BIOMARIN PHARMACEUTICAL INC

Director

NMRA

Neumora Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (24 total)

AGIO
AGIOS PHARMACEUTICALS, INC.
Jun 18, 2026
Award(A)
Restricted stock units
Direct
2.9K shares-
AGIO
AGIOS PHARMACEUTICALS, INC.
Jun 18, 2026
Exercise(M)
Direct
2.8K shares-
AGIO
AGIOS PHARMACEUTICALS, INC.
Jun 18, 2026
Award(A)
Stock options (right to buy)
Direct
15K shares-
KYNB
KYNTRA BIO, INC.
Jun 12, 2026
Award(A)
Stock Option (Right to Buy)
Direct
7K shares-
BMRN
BIOMARIN PHARMACEUTICAL INC
Jun 2, 2026
Award(A)
Direct
7.5K shares-
NMRA
Neumora Therapeutics, Inc.
May 27, 2026
Award(A)
Stock Option (Right to Buy)
Direct
80K shares-
AGIO
AGIOS PHARMACEUTICALS, INC.
Jun 20, 2025
Exercise(M)
Direct
2.1K shares-
AGIO
AGIOS PHARMACEUTICALS, INC.
Jun 18, 2025
Award(A)
Stock options (right to buy)
Direct
15.8K shares-
AGIO
AGIOS PHARMACEUTICALS, INC.
Jun 18, 2025
Award(A)
Restricted stock units
Direct
2.8K shares-
FGEN
FIBROGEN INC
Jun 4, 2025
Award(A)
Stock Option (Right to Buy)
Direct
120K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
95.6K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
27.8K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
28.6K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
95.6K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
27.8K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
28.6K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
80K shares-
BMRN
BIOMARIN PHARMACEUTICAL INC
May 20, 2025
Award(A)
Direct
6.7K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Award(A)
Stock Option (Right to Buy)
Direct
28.6K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
27.8K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Award(A)
Stock Option (Right to Buy)
Direct
27.8K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Award(A)
Stock Option (Right to Buy)
Direct
95.6K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
28.6K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
95.6K shares-

		Type	Shares	Price		Ownership
Jun 18, 2026	AGIO AGIOS PHARMACEUTICALS, INC.	Award(A) Restricted stock units	2,927	-	-	Direct
Jun 18, 2026	AGIO AGIOS PHARMACEUTICALS, INC.	Exercise(M)	2,816	-	$0	Direct
Jun 18, 2026	AGIO AGIOS PHARMACEUTICALS, INC.	Award(A) Stock options (right to buy)	14,950	-	-	Direct
Jun 12, 2026	KYNB KYNTRA BIO, INC.	Award(A) Stock Option (Right to Buy)	7,000	-	-	Direct
Jun 2, 2026	BMRN BIOMARIN PHARMACEUTICAL INC	Award(A)	7,490	-	$0	Direct
May 27, 2026	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	80,000	-	-	Direct
Jun 20, 2025	AGIO AGIOS PHARMACEUTICALS, INC.	Exercise(M)	2,120	-	-	Direct
Jun 18, 2025	AGIO AGIOS PHARMACEUTICALS, INC.	Award(A) Stock options (right to buy)	15,768	-	-	Direct
Jun 18, 2025	AGIO AGIOS PHARMACEUTICALS, INC.	Award(A) Restricted stock units	2,816	-	-	Direct
Jun 4, 2025	FGEN FIBROGEN INC	Award(A) Stock Option (Right to Buy)	120,000	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	95,586	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	27,802	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	28,571	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	95,586	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	27,802	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	28,571	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	80,000	-	-	Direct
May 20, 2025	BMRN BIOMARIN PHARMACEUTICAL INC	Award(A)	6,650	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	28,571	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	27,802	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	27,802	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	95,586	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	28,571	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	95,586	-	-	Direct

1-24 of 24 transactions

About Ho Maykin

Ho Maykin (SEC CIK 0001646395) files insider reports with the SEC as Director of AGIOS PHARMACEUTICALS, INC. (AGIO), Director of KYNTRA BIO, INC. (KYNB) and Director of BIOMARIN PHARMACEUTICAL INC (BMRN). Signal8 also holds filings tied to 1 other company.

Signal8 holds 9 ownership filings by Ho Maykin, all Form 4s, filed between Feb 18, 2025 and Jun 23, 2026. Those filings report 24 transactions, from Feb 13, 2025 to Jun 18, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Ho Maykin's filings is in SAN RAFAEL, CA.

Recent filings by Ho Maykin

Jun 18, 2026: Grant or award of AGIO derivative securities (Form 4, code A).
Jun 18, 2026: Option exercise of AGIO shares (Form 4, code M).
Jun 18, 2026: Grant or award of AGIO derivative securities (Form 4, code A).
Jun 12, 2026: Grant or award of KYNB derivative securities (Form 4, code A).
Jun 2, 2026: Grant or award of BMRN shares (Form 4, code A).

Other insiders filing for AGIOS PHARMACEUTICALS, INC. (AGIO)

Gheuens Sarah, Chief Medical Officer
Backstrom Jay T., Director
Ballal Rahul D., Director
CAPELLO JEFFREY D, Director
Foster-Cheek Kaye I, Director
FOUSE JACQUALYN A, Director

How to read Form 4 transaction codes